Neuronox® Siax® Botulift® Cunox® and Meditoxin®
- Botulinum toxin
- History
Glabellar frown lines
Product Information
Botulinum toxin

   A protein produced by the bacterium Clostridium botulinum, and is considered the most powerful neurotoxin ever discovered. Botulinum toxin causes botulism, a serious and life-threatening illness in humans and animals. It has been widely used not only in the cosmetic field, including facial wrinkle reduction, but also in the therapeutic field, for people with blepharospasm, focal spasticity in cerebral palsy, etc.

Various indications Blepharospasm and strabismus In the early 1980s, university-based ophthalmologists in the U.S.A. and Canada further refined the use of botulinum toxin as a therapeutic agent. By 1985, a scientific protocol of injection sites and dosage had been empirically determined for treatment of blepharospasm and strabismus. The beneficial effects of the injection lasted 4~6 months. Cosmetic Canadian ophthalmologist and dermatologist physicians Carruthers JD and Carruthers JA were the first to publish a study on botulinum toxin for the treatment of glabellar frown lines in 1992. After formal trials, on April 12, 2002, the FDA announced regulatory approval of botulinum toxin type A to temporarily improve the appearance of moderate-to-severe glabellar frown lines between the eyebrows. Muscle spasms The acceptance of botulinum toxin use for the treatment of muscle pain disorders is growing, with approvals pending in many European countries. The efficacy of botulinum toxin in treating a variety of other medical conditions (including prostatic dysfunction, asthma, and others) is an area of continued study.

Developing indications

Medytox Mini Poll

Which area do your patients most want to be treated with Neuronox?
a. Glabellar lines
b. Crow’s feet
c. Forehead lines
d. Masseter
e. Calf
MoreMedytox News